"On the R&D side, we spent roughly $1 billion on R&D, and you could see the -- a big chunk of that is for innovative specialty products. We have about 30 development projects ongoing, about two-thirds of those are biopharmaceuticals. And we don't really want to share that with anybody right now. The reason is that, we are in the restructuring right now this year and last year, but our plan is to share more with you once we finish this year. So once we get to February of next year, we will share a bit more with you on what is our pipeline, what are the different projects we have. We have some really exciting projects. There is some overlap in the actual biopharmaceutical R&D machine in terms of pilot plans, clinical development, the early phases. So we think we can do very efficient R&D and we can keep supporting the specialty business at the size that we have it now. Of course, it's only a part of our business that's a specialty business and that's where we need to renew and keep on supporting and we think we can do that with a total spend of around $1 billion."
Kare Schultz -- President and Chief Executive Officer
Nächstes Jahr im Februar wissen wir mehr. Das wird niemals in den aktuellen Erwartungen der Analysten enthalten sein. Warum sollte bei 30 Kandidaten nicht auch der ein oder andere Volltreffer dabei sein? |